© Drug Hunter Inc. 2018-2023
Home > AZD0364
oral reversible ERK1/2 kinase inhibitor
combo eff. w/ MEKi in mKRAS model; in Ph. I
from historical kinase sel. data, SBDD + opt.
Mol. Cancer Ther. Dec. 3, 2020
AstraZeneca, Cambridge, UK
AstraZeneca oral reversible ERK1/2 kinase inhibitor
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
Molecules of the Month
Molecule of the Year